Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
Copyright © 2021 Elsevier Ltd. All rights reserved..
BACKGROUND: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19.
METHODS: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027.
FINDINGS: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of -2·7 percentage points (95% CI -7·3 to 1·9). The 28-day all-cause mortality was 8% (n=62) for baricitinib and 13% (n=100) for placebo (hazard ratio [HR] 0·57 [95% CI 0·41-0·78]; nominal p=0·0018), a 38·2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. The 60-day all-cause mortality was 10% (n=79) for baricitinib and 15% (n=116) for placebo (HR 0·62 [95% CI 0·47-0·83]; p=0·0050). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups.
INTERPRETATION: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.
FUNDING: Eli Lilly and Company.
TRANSLATIONS: For the French, Japanese, Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
| Errataetall: |
CommentIn: Lancet Respir Med. 2021 Dec;9(12):1349-1351. - PMID 34480862 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
The Lancet. Respiratory medicine - 9(2021), 12 vom: 04. Dez., Seite 1407-1418 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marconi, Vincent C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.01.2022 Date Revised 07.12.2022 published: Print-Electronic ClinicalTrials.gov: NCT04421027 CommentIn: Lancet Respir Med. 2021 Dec;9(12):1349-1351. - PMID 34480862 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2213-2600(21)00331-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330232940 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330232940 | ||
| 003 | DE-627 | ||
| 005 | 20231225210837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2213-2600(21)00331-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM330232940 | ||
| 035 | |a (NLM)34480861 | ||
| 035 | |a (PII)S2213-2600(21)00331-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marconi, Vincent C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) |b a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04421027 | ||
| 500 | |a CommentIn: Lancet Respir Med. 2021 Dec;9(12):1349-1351. - PMID 34480862 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19 | ||
| 520 | |a METHODS: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027 | ||
| 520 | |a FINDINGS: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of -2·7 percentage points (95% CI -7·3 to 1·9). The 28-day all-cause mortality was 8% (n=62) for baricitinib and 13% (n=100) for placebo (hazard ratio [HR] 0·57 [95% CI 0·41-0·78]; nominal p=0·0018), a 38·2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. The 60-day all-cause mortality was 10% (n=79) for baricitinib and 15% (n=116) for placebo (HR 0·62 [95% CI 0·47-0·83]; p=0·0050). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups | ||
| 520 | |a INTERPRETATION: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19 | ||
| 520 | |a FUNDING: Eli Lilly and Company | ||
| 520 | |a TRANSLATIONS: For the French, Japanese, Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Azetidines |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a baricitinib |2 NLM | |
| 650 | 7 | |a ISP4442I3Y |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Ramanan, Athimalaipet V |e verfasserin |4 aut | |
| 700 | 1 | |a de Bono, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Kartman, Cynthia E |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Venkatesh |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Piruzeli, Maria Lucia B |e verfasserin |4 aut | |
| 700 | 1 | |a Goldman, Jason D |e verfasserin |4 aut | |
| 700 | 1 | |a Alatorre-Alexander, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a de Cassia Pellegrini, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Estrada, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Som, Mousumi |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Anabela |e verfasserin |4 aut | |
| 700 | 1 | |a Chakladar, Sujatro |e verfasserin |4 aut | |
| 700 | 1 | |a Crowe, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Reis, Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Ely, E Wesley |e verfasserin |4 aut | |
| 700 | 0 | |a COV-BARRIER Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Mi-Young |e investigator |4 oth | |
| 700 | 1 | |a Akasbi, Miriam |e investigator |4 oth | |
| 700 | 1 | |a Alatorre-Alexander, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Altclas, Javier David |e investigator |4 oth | |
| 700 | 1 | |a Ariel, Federico |e investigator |4 oth | |
| 700 | 1 | |a Ariza, Horacio Alberto |e investigator |4 oth | |
| 700 | 1 | |a Atkar, Chandrasekhar |e investigator |4 oth | |
| 700 | 1 | |a Bertetti, Anselmo |e investigator |4 oth | |
| 700 | 1 | |a Bhattacharya, Meenakshi |e investigator |4 oth | |
| 700 | 1 | |a Briones, Maria Luisa |e investigator |4 oth | |
| 700 | 1 | |a Budhraja, Akshay |e investigator |4 oth | |
| 700 | 1 | |a Burza, Aaliya |e investigator |4 oth | |
| 700 | 1 | |a Camacho Ortiz, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Caricchio, Roberto |e investigator |4 oth | |
| 700 | 1 | |a Casas, Marcelo |e investigator |4 oth | |
| 700 | 1 | |a Cevoli Recio, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Choi, Won Suk |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Emilia |e investigator |4 oth | |
| 700 | 1 | |a Comulada-Rivera, Angel |e investigator |4 oth | |
| 700 | 1 | |a Cook, Paul |e investigator |4 oth | |
| 700 | 1 | |a Cornejo Juarez, Dora Patricia |e investigator |4 oth | |
| 700 | 1 | |a Daniel, Carnevali |e investigator |4 oth | |
| 700 | 1 | |a Degrecci Relvas, Luiz Fernando |e investigator |4 oth | |
| 700 | 1 | |a Dominguez Cherit, Jose Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Ellerin, Todd |e investigator |4 oth | |
| 700 | 1 | |a Enikeev, Dmitry |e investigator |4 oth | |
| 700 | 1 | |a Erico Tanni Minamoto, Suzana |e investigator |4 oth | |
| 700 | 1 | |a Estrada, Vicente |e investigator |4 oth | |
| 700 | 1 | |a Fiss, Elie |e investigator |4 oth | |
| 700 | 1 | |a Furuichi, Motohiko |e investigator |4 oth | |
| 700 | 1 | |a Giovanni Luz, Kleber |e investigator |4 oth | |
| 700 | 1 | |a Goldman, Jason D |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Omar |e investigator |4 oth | |
| 700 | 1 | |a Gordeev, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Gruenewald, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Hamamoto Sato, Victor Augusto |e investigator |4 oth | |
| 700 | 1 | |a Heo, Eun Young |e investigator |4 oth | |
| 700 | 1 | |a Heo, Jung Yeon |e investigator |4 oth | |
| 700 | 1 | |a Hermida, Maria |e investigator |4 oth | |
| 700 | 1 | |a Hirai, Yuji |e investigator |4 oth | |
| 700 | 1 | |a Hutchinson, David |e investigator |4 oth | |
| 700 | 1 | |a Iastrebner, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Ioachimescu, Octavian |e investigator |4 oth | |
| 700 | 1 | |a Jain, Manish |e investigator |4 oth | |
| 700 | 1 | |a Juliani Souza Lima, Maria Patelli |e investigator |4 oth | |
| 700 | 1 | |a Khan, Akram |e investigator |4 oth | |
| 700 | 1 | |a Kremer, Andreas E |e investigator |4 oth | |
| 700 | 1 | |a Lawrie, Thomas |e investigator |4 oth | |
| 700 | 1 | |a MacElwee, Mark |e investigator |4 oth | |
| 700 | 1 | |a Madhani-Lovely, Farah |e investigator |4 oth | |
| 700 | 1 | |a Malhotra, Vinay |e investigator |4 oth | |
| 700 | 1 | |a Martínez Resendez, Michel Fernando |e investigator |4 oth | |
| 700 | 1 | |a McKinnell, James |e investigator |4 oth | |
| 700 | 1 | |a Milligan, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Minelli, Cesar |e investigator |4 oth | |
| 700 | 1 | |a Moran Rodriguez, Miguel Angel |e investigator |4 oth | |
| 700 | 1 | |a Parody, Maria Leonor |e investigator |4 oth | |
| 700 | 1 | |a Paulin, Priscila |e investigator |4 oth | |
| 700 | 1 | |a Pellegrini, Rita de Cassia |e investigator |4 oth | |
| 700 | 1 | |a Pemu, Priscilla |e investigator |4 oth | |
| 700 | 1 | |a Procopio Carvalho, Ana Carolina |e investigator |4 oth | |
| 700 | 1 | |a Puoti, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Purow, Joshua |e investigator |4 oth | |
| 700 | 1 | |a Ramesh, Mayur |e investigator |4 oth | |
| 700 | 1 | |a Rea Neto, Alvaro |e investigator |4 oth | |
| 700 | 1 | |a Rea Neto, Alvaro |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Philip |e investigator |4 oth | |
| 700 | 1 | |a Rodrigues, Cristhieni |e investigator |4 oth | |
| 700 | 1 | |a Rojas Velasco, Gustavo |e investigator |4 oth | |
| 700 | 1 | |a Saraiva, Jose Francisco Kerr |e investigator |4 oth | |
| 700 | 1 | |a Scheinberg, Morton |e investigator |4 oth | |
| 700 | 1 | |a Schreiber, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Scublinsky, Dario |e investigator |4 oth | |
| 700 | 1 | |a Sevciovic Grumach, Anete |e investigator |4 oth | |
| 700 | 1 | |a Shawa, Imad |e investigator |4 oth | |
| 700 | 1 | |a Simon Campos, Jesus |e investigator |4 oth | |
| 700 | 1 | |a Sofat, Nidhi |e investigator |4 oth | |
| 700 | 1 | |a Som, Mousumi |e investigator |4 oth | |
| 700 | 1 | |a Spinner, Christoph D |e investigator |4 oth | |
| 700 | 1 | |a Sprinz, Eduardo |e investigator |4 oth | |
| 700 | 1 | |a Stienecker, Roger |e investigator |4 oth | |
| 700 | 1 | |a Suarez, Jose |e investigator |4 oth | |
| 700 | 1 | |a Tachikawa, Natsuo |e investigator |4 oth | |
| 700 | 1 | |a Tahir, Hasan |e investigator |4 oth | |
| 700 | 1 | |a Tiffany, Brian |e investigator |4 oth | |
| 700 | 1 | |a Vishnevsky, Alexander |e investigator |4 oth | |
| 700 | 1 | |a Westheimer Cavalcante, Adilson |e investigator |4 oth | |
| 700 | 1 | |a Zirpe, Kapil |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Respiratory medicine |d 2013 |g 9(2021), 12 vom: 04. Dez., Seite 1407-1418 |w (DE-627)NLM232005109 |x 2213-2619 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:12 |g day:04 |g month:12 |g pages:1407-1418 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2213-2600(21)00331-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 12 |b 04 |c 12 |h 1407-1418 | ||